Frontlight ResearchEarly access
Taking people in GermanyPhase 4
Shingrix vaccine safety in people with psoriasis or psoriatic arthritis
Tests the Shingrix shingles vaccine in adults with psoriasis or psoriatic arthritis.
Key facts
- Who runs it
- Justus-Liebig-Universitaet Giessen
- Where
- Bad Bentheim, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Marburg, Merzig, Muenster, Munich, Straubing, Wetzlar, and Wuppertal, GermanySee the 16 sites
- Registry title
- Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 336 people, planned
- Started
- 22 Nov 2023
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with psoriasis or psoriatic arthritis whose disease is under control. It studies the safety of the Shingrix shingles vaccine.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Psoriasis vulgaris and/or psoriatic arthritis with low disease activity: PASI ≤ 9 for skin disease and DAPSA ≤ 14 for joint disease, depending on the form.
- Earlier treatment
- No earlier Shingrix (recombinant zoster vaccine). No other shingles or chickenpox vaccine in the last 12 months. No disease flare with treatment escalation in the last 6 months.
Main reasons for not taking part
- Pregnant or breast feeding
- History of shingles (herpes zoster) or a chronic infectious disease
- Cancer not treated with the aim of removing all of the disease, or treated cancer with signs of disease within the last 5 years
- Allergy to Shingrix or any of its ingredients
- Another vaccine given too close to the Shingrix dose (30 days for live virus and mRNA vaccines, 8 days for inactivated or subunit vaccines)
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Diagnosis of psoriasis vulgaris and/or psoriatic arthritis
- Score thresholds depending on disease: a. PASI ≤ 9 and DAPSA ≤ 14 in patients having both psoriasis and psoriasis arthritis b. PASI ≤ 9 in patients presenting with psoriasis vulgaris only c. DAPSA ≤ 14 in patients presenting with psoriasis arthritis without major skin involvement
- Age ≥ 18 and ≤ 75 years
- Written informed consent
- Women of childbearing potential should use at least one of the following contraceptive measures up until 2 months after the second vaccination (week 24 of the study): - progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action - male or female condom with or without spermicide - cap, diaphragm or sponge with spermicide
Who cannot take part
- Concurrent participation in another interventional AMG trial
- Prior administration of recombinant zoster vaccine (RZV) at any point in time, or any other herpes zoster or varicella vaccine received less than12 months ago
- Previous or current history of HZ
- Live virus and mRNA vaccines cannot be administered within 30 days (before/after) RZV and inactivated/ subunit vaccines within 8 days (before/after) RZV
- Patients with disease flares within the past 6 months. A disease flare is defined as any therapeutic escalation during the past 6 months prior to screening. This includes new onset of concomitant immunomodulation, change of ongoing immunomodulation, and/or use of glucocorticoids ≥ 10 mg per day prednisolone equivalent
- History of chronic infectious disease
- Past or current history of cancer not curatively treated. Curatively treated malignancies must be without evidence of disease for a minimumof 5 years upon enrollment
- Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere withcompletion of the study
- Hypersensitivity to the active substance or to any of the other substance of Shingrix
- Subject pregnant or breast feeding
Where in Germany
- Thermalsole und Schwefelbad Bentheim GmbHBad Bentheim, GermanyTaking people
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Infektio Research GmbH & Co. KGFrankfurt Am Main, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- ICH Study Center Gmbh & Co. KGHamburg, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Rheumatologische Praxis Hannover GbRHanover, GermanyTaking people
- Philipps-Universitaet MarburgMarburg, GermanyTaking people
- Hms GmbHMerzig, GermanyTaking people
- Universitaet MuensterMuenster, GermanyTaking people
- Universitaetsklinikum Muenster AöRMuenster, GermanyTaking people
- Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
- Barmherzige Brueder gemeinnuetzige Traeger GmbHStraubing, GermanyTaking people
- Studienteam Lahn-Dill-Siegerland GbRWetzlar, GermanyTaking people
- Klinikverbund St. Antonius und St. Josef GmbHWuppertal, GermanyTaking people
About the trial
What the trial wants to find out
To investigate the safety of the vaccine in terms of underlying disease activity in patients with psoriasis or psoriatic arthritis.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Safety and immunogenicity of Shingrix vaccination in patients suffering from Psoriasis or Psoriatic arthritis
- Plain-language title
- Shingrix vaccine safety in people with psoriasis or psoriatic arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 April 2026